IL325730A - Derivatives of 2-phenoxy-1-(4-(alkylsulfonyl)piperidin-1-yl)ethan-1-one and 3-phenyl-1-(4-(alkylsulfonyl)piperidin-1-yl)prop-2-en-1-one as GIPIR183 antagonists for the treatment of chronic pain - Google Patents
Derivatives of 2-phenoxy-1-(4-(alkylsulfonyl)piperidin-1-yl)ethan-1-one and 3-phenyl-1-(4-(alkylsulfonyl)piperidin-1-yl)prop-2-en-1-one as GIPIR183 antagonists for the treatment of chronic painInfo
- Publication number
- IL325730A IL325730A IL325730A IL32573026A IL325730A IL 325730 A IL325730 A IL 325730A IL 325730 A IL325730 A IL 325730A IL 32573026 A IL32573026 A IL 32573026A IL 325730 A IL325730 A IL 325730A
- Authority
- IL
- Israel
- Prior art keywords
- piperidin
- alkylsulfonyl
- gpr183
- ethan
- prop
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D211/54—Sulfur atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Pain & Pain Management (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Immunology (AREA)
- Hydrogenated Pyridines (AREA)
- Rheumatology (AREA)
- Pulmonology (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Dermatology (AREA)
- Epidemiology (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| FI20237131 | 2023-07-05 | ||
| PCT/FI2024/050372 WO2025008574A1 (en) | 2023-07-05 | 2024-07-04 | 2-phenoxy-1-(4-(alkylsulfonyl)piperidin-1-yl)ethan-1-one and 3-phenyl-1-(4-(alkylsulfonyl)piperidin-1-yl)prop-2-en-1-one derivatives as gpr183 antagonists for the treatment of chronic pain |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IL325730A true IL325730A (en) | 2026-03-01 |
Family
ID=91950461
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL325730A IL325730A (en) | 2023-07-05 | 2024-07-04 | Derivatives of 2-phenoxy-1-(4-(alkylsulfonyl)piperidin-1-yl)ethan-1-one and 3-phenyl-1-(4-(alkylsulfonyl)piperidin-1-yl)prop-2-en-1-one as GIPIR183 antagonists for the treatment of chronic pain |
Country Status (11)
| Country | Link |
|---|---|
| EP (1) | EP4739656A1 (de) |
| KR (1) | KR20260035942A (de) |
| CN (1) | CN121794256A (de) |
| AR (1) | AR133165A1 (de) |
| AU (1) | AU2024290016A1 (de) |
| CO (1) | CO2026000808A2 (de) |
| IL (1) | IL325730A (de) |
| MX (1) | MX2025015183A (de) |
| PE (1) | PE20260501A1 (de) |
| TW (1) | TW202517611A (de) |
| WO (1) | WO2025008574A1 (de) |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1948597A1 (de) * | 2005-10-21 | 2008-07-30 | Vertex Pharmaceuticals Incorporated | Derivate zur modulation von ionenkanälen |
| WO2015048570A2 (en) | 2013-09-26 | 2015-04-02 | Sanford-Burnham Medical Research Institute | Ebi2 modulators |
| US11919895B2 (en) | 2019-10-25 | 2024-03-05 | Saint Louis University | GPR183 antagonists for the treatment of pain |
| MX2024004722A (es) | 2021-10-18 | 2024-07-24 | Nanjing Immunophage Biotech Co Ltd | Compuestos y sus usos como inhibidores de gpr183. |
-
2024
- 2024-07-02 TW TW113124694A patent/TW202517611A/zh unknown
- 2024-07-04 KR KR1020267003568A patent/KR20260035942A/ko active Pending
- 2024-07-04 PE PE2026000009A patent/PE20260501A1/es unknown
- 2024-07-04 WO PCT/FI2024/050372 patent/WO2025008574A1/en not_active Ceased
- 2024-07-04 AU AU2024290016A patent/AU2024290016A1/en active Pending
- 2024-07-04 EP EP24742983.0A patent/EP4739656A1/de active Pending
- 2024-07-04 CN CN202480044333.6A patent/CN121794256A/zh active Pending
- 2024-07-04 IL IL325730A patent/IL325730A/en unknown
- 2024-07-04 AR ARP240101738A patent/AR133165A1/es unknown
-
2025
- 2025-12-15 MX MX2025015183A patent/MX2025015183A/es unknown
-
2026
- 2026-01-26 CO CONC2026/0000808A patent/CO2026000808A2/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| AR133165A1 (es) | 2025-09-03 |
| TW202517611A (zh) | 2025-05-01 |
| CN121794256A (zh) | 2026-04-03 |
| EP4739656A1 (de) | 2026-05-13 |
| MX2025015183A (es) | 2026-02-03 |
| KR20260035942A (ko) | 2026-03-13 |
| AU2024290016A1 (en) | 2026-02-19 |
| CO2026000808A2 (es) | 2026-02-13 |
| PE20260501A1 (es) | 2026-02-27 |
| WO2025008574A1 (en) | 2025-01-09 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2020008559A (es) | Compuestos heterocíclicos como inhibidores de la quinasa. | |
| PL2298743T3 (pl) | Inhibitory kinaz P38 na bazie 5-członowych heterocykli | |
| WO2005063766A3 (en) | Bicyclic heterocyclic p-38 kinase inhibitors | |
| MX2020010484A (es) | Derivados de heterociclilos sustituidos como inhibidores de cdk. | |
| IL288508A (en) | History of n-(5-(6-ethoxypyrazin-2-yl)pyridin-2-yl)-4-(2-(methylsulfonamido)pyrimidin-4-yl)tetrahydro-h2-pyran-4-carboxamide and related compounds as human ctps1 inhibitors to treat proliferative diseases | |
| PH12015501958A1 (en) | Processes and intermediates for making a jak inhibitor | |
| MX2009011810A (es) | Tiazoles y pirazoles utiles como inhibidores de cinasa. | |
| MX2009012719A (es) | Tiazoles y pirazoles utiles como inhibidores de cinasa. | |
| ZA200706740B (en) | Quinazolinone T-type calcium channel antagonists | |
| TNSN05044A1 (en) | Use of ikappab kinase inhibitors for the treatment of pain | |
| ATE534632T1 (de) | Thiazole, imidazole und pyrazole als proteinkinasehemmer | |
| IL291665A (en) | Inhibitors of receptor interaction with protein kinase i for the treatment of disease | |
| EP4051282A4 (de) | Verfahren zur behandlung von krebs bei biomarker-identifizierten patienten mit inhibitoren der cyclin-abhängigen kinase 7 (cdk7) | |
| IL195900A0 (en) | Piperazinyl derivatives useful in the treatment of gpr38 receptor mediated diseases | |
| PL3972604T3 (pl) | Inhibitor kinazy tyrozynowej brutona do zastosowania w leczeniu przewlekłej pokrzywki spontanicznej | |
| IL288924A (en) | Casein kinase 1 inhibitors for use in the treatment of diseases associated with the expression of dux4 such as muscular dystrophy and cancer | |
| ZA202101118B (en) | A substituted amino-pyrimidine compound for use in a method for treatment and prevention of multiple sclerosis | |
| HUE069498T2 (hu) | Para-hidrokinon-származékok VEGF, TNF és/vagy il inhibitorokként neuroinflammatorikus betegségek kezelésére | |
| AU2024290016A1 (en) | 2-phenoxy-1-(4-(alkylsulfonyl)piperidin-1-yl)ethan-1-one and 3-phenyl-1-(4-(alkylsulfonyl)piperidin-1-yl)prop-2-en-1-one derivatives as gpr183 antagonists for the treatment of chronic pain | |
| CA3296824A1 (en) | 2-phenoxy-1-(4-(alkylsulfonyl)piperidin-1-yl)ethan-1-one and 3-phenyl-1-(4-(alkylsulfonyl)piperidin-1-yl)prop-2-en-1-one derivatives as gpr183 antagonists for the treatment of chronic pain | |
| CL2004001430A1 (es) | Compuestos derivados de imidazol sustituidos con heteroarilo; proceso de preparacion;y uso en la prevencion y tratamiento de trastornos mediados por el receptor mglur5, trastornos neurologicos agudos y/o cronicos tales como la ansiedad y dolor cronic | |
| DK1503764T3 (da) | 5-HT4-receptor-antagonister til behandling af hjertesvigt | |
| HK40079169A (en) | Inhibitors of receptor interacting protein kinase i for the treatment of disease | |
| HK40087155A (en) | Composition for use in the treatment of apol1-associated disease | |
| TNSN05307A1 (en) | 5-membered heterocycle-based p38 kinase inhibitors |